Extended Advanced Registration Discount Ends TONIGHT, Monday, December 3rd!!!

Rooms are Almost Gone, Reserve Your Room TODAY!
Sonesta Fort Lauderdale Beach Hotel
999 N Fort Lauderdale Beach Blvd
Fort Lauderdale, FL 33304

  Reserve your hotel room on or before Wednesday, December 19, 2018 to receive the meeting discount rate.

Standard Guest Room - $259/night
*The group rate does not include the applicable state and local taxes.
Offering Up to 12 CE Hours!!

Ingrid Lindberg
CEO and Founding Partner
Chief Customer
Keynote: Becoming Customer Centric

So often companies fail to really look outside and listen to what their customers want.  Learn strategies on how to transform companies to be better listeners-a key step on the road to being customer-centric. Ingrid has taken 200 year old financial services companies and health care companies (B2B) and made them into extremely profitable B2C consumer brands.
Ross Caputo
Eagle Analytical Services
Insanitary Conditions at Compounding Facilities

This session will focus on understanding the FDA's recently revised guidance on Insanitary Conditions at Compounding Facilities and its regulatory implications. Attendees will learn to identify insanitary conditions in their facilities, correct those conditions, and implement quality and operational systems to prevent future recurrences.
L. Rad Dillon  
LR Dillon Pharmacy Consulting

USP <800> Waste and HazMat Disposal options For Compounding

This session will present a number of important issues concerning hazardous drugs (HDs) remain either unaddressed or inadequately covered in USP <800>, including details on HD disposal, when, where and what personal protective equipment (PPE) to utilize, the assessment of risk (AOR), and the decontamination, cleaning and disinfection of work areas and equipment. This presentation will provide best practice recommendations on these topics in an easy to use format.
Ken Speidel
BS Pharm, PharmD, RPh, FIACP, FACA, 
LP3 Network
Routes, Dosages, Delivery Systems, and Devices - Special Considerations for Hormone Restoration Therapy

In this presentation, participants will review the various routes of delivery employed in hormone restoration therapy, with a focus on special considerations related to potential advantages and disadvantages of these routes. Common dosage forms will also be presented, highlighting typical uses and general guidance for different scenarios. Delivery systems and devices will also be addressed, with respect to providing the best patient care and safety. Following the presentation, a question and answer period will help to address any remaining questions.
Charles Lipeles
V.P. of U.S. Operations
Mecart Cleanrooms

Cleanroom Design

This session will discuss the various factors that compounding pharmacists and owners must consider prior to investing in a new cleanroom to meet the new standards of USP <797> and USP <800>.  We will cover varying topics ranging from financials to an analysis of stock built rooms vs modular rooms.  The end goal is to make you a more knowledgeable consumer and help you in this challenging (and expensive) process.
Suzanne Keyes
Keyes' Compounding & 180 Wellness Center
Mark Burger Hour: Pharmacogenomics & The Pharmacist

This session is to encourage practitioners to step outside their comfort zone of traditional pharmacy methods and create revenue opportunities through specialized advanced consultations. 
Kate Placzek
ZRT Laboratories

Glucocorticoids & Catecholamines: Insights for Addressing Acute and Chronic Stress

This presentation will introduce a more comprehensive approach to evaluating stress hormones to improve treatments for patient care. A traditionally used tool for assessing adrenal hormone function has been the 4-point circadian cortisol curve in saliva or urine, addressing just one part of a multi-factorial stress response. The added benefit of dried urine is that epinephrine and norepinephrine can be measured at the same time as cortisol, allowing the practitioner to get a more complete picture of the stress response system thereby opening multiple avenues for proper treatment to improve patient outcomes.
Jon Pritchett
PharmD, RPh, Associate Director Pharmacy
Accreditation Commission for Health Care  ( ACHC)  

Upcoming Changes to USP <795> <797>

This session will provide an overview of the proposed changes to USP <795> and <797> and discuss their timeline for implementation. Which will allow pharmacists and Technicians an opportunity to anticipate upcoming changes to best-practices in the compounding industry.

Panel Discussion on USP Standards

Both USP <795> Pharmaceutical Compounding - Nonsterile Preparations and USP <797> Pharmaceutical Compounding - Sterile Preparations are under revision. USP <800> Hazards Drugs - Handling in Healthcare Settings has been published but implementation has been delayed to align with <795> and <797>. This session will include discussion with pharmacists and consultants to help participants understand facility, personnel, and process requirements as well as understand what is being proposed but is not yet official.
Eric Cropp
RPh, Second Victim Advocate, Pharmcon/ISMP
Lessons Learned: How to Implement a "Second Victims" Program at Your Facility

This session will discuss how to develop a Second Victims Program and the necessary tools to make it work in your facility.

Kimberly Kieffer
CPhT, Director of Corporate Relations
Empower Pharmacy
Quality by Design - Using aspects cGMP to improve quality in the 503A Pharmacy

Consider how Current Good Manufacturing Practices (cGMP) can impact quality improvement in the 503A compounding setting. cGMP as prescribed in 21 CFR parts 210 and 211 offers a frame work to the pharmaceutical industry to build quality into every process design to assure only the best final products are released. Many of these concepts can be utilized in the compounding pharmacy with little to no added expense and can vastly improve documentation efforts, process control and quality assurance. This presentation will explore using the available guidance for industry to augment USP <795> and <797> in an effort to improve and elevate quality management in the compounding pharmacy.
Thomas Kupiec
PhD, President & CEO
ARL Bio Pharma
What is Required for Stability Testing?

The practice of assigning beyond-use dates for compounded sterile preparations (CPSs) is complicated and often misunderstood. Participants will gather an understanding of the factors affecting product stability and the requirements for maintaining the stability of a drug product. This session will review how 503A pharmacies and 503B outsourcing facilities can use stability data to improve the quality of sterile and non-sterile compounded drug products.

Click here
 to view the full #EduCon2019 Schedule at A Glance
IACP | 281.933.8400 | 281.495.0602|   iacpinfo@iacprx.org |   iacprx.org